Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials.

Giovanni MussoRoberto GambinoMaurizio CassaderElena Paschetta

Published in: BMJ (Clinical research ed.) (2019)

In type 1 diabetes, sotagliflozin improves glycaemic and non-glycaemic outcomes and reduces hypoglycaemia rate and severe hypoglycaemia. The risk of diabetic ketoacidosis could be minimised by appropriate patient selection and down-titration of the basal insulin dose.

Keyphrases

type diabetes
glycemic control
cardiovascular disease
insulin resistance
case report
early onset
wound healing